Alector, Inc. (ALEC)

In October 2025, Alector's stock plunged after its Phase 3 trial for latozinemab failed, leading to trial discontinuation and workforce reduction. In December 2025, Neil Berkley was appointed CFO. As of early January 2026, the stock had increased by 28.86% in the past month and 17.9% year-to-date, but was still down 20.79% over the preceding year, with a price of $1.60 as of January 5, 2026.

Alector, Inc. does not have traditional product sales, and its revenue is primarily derived from strategic collaboration agreements. Therefore, the concept of demand seasonality does not apply to Alector, Inc. in its current operational stage.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic approaches for neurodegenerative diseases. The company leverages human genetics, immunology, and neuroscience to restore healthy immune function to the brain. Its pipeline includes Latozinemab (AL001) in Phase 3 trials for frontotemporal dementia and explored for other diseases, Nivisnebart (AL101/GSK4527226) in Phase 2 for early Alzheimer's, AL002 in Phase 2 for Alzheimer's, AL003 in Phase 1 for Alzheimer's, AL044 targeting MS4A4A for Alzheimer's, and Alector Brain Carrier (ABC) for enhanced therapeutic delivery. The company uses a hybrid business model with internal R&D and collaborations with GSK and Adimab.

Alector, Inc. is headquartered in South San Francisco, California, and operates a manufacturing facility in Milpitas, California. Its revenue is derived from global strategic partnership agreements.

Alector's brand reputation was negatively impacted by the failure of its Phase 3 clinical trial for latozinemab in October 2025, leading to a stock price drop and workforce reduction. An investigation was initiated in December 2025 by Levi & Korsinsky concerning possible violations of federal securities laws related to the trial results, which could further affect the company's reputation.

Alector, Inc. has significant institutional ownership, with 85.83% of its stock held by institutions including Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Individual insiders own 9.70% of the company's stock, with Polaris Venture Management Co VI LLC being the largest individual shareholder. Key individual owners and insiders include Terrance McGuire, Arnon Rosenthal, and Neil Lindsay Berkley.